Ono swoops on Deciphera in $2.4 billion takeover
Japan’s Ono Pharma has bolstered its cancer pipeline with a $2.4 billion agreement to buy Deciphera Pharma of the US and its fast-growing gastrointestinal stromal tumour (
Newsletters and Deep Dive digital magazine
Japan’s Ono Pharma has bolstered its cancer pipeline with a $2.4 billion agreement to buy Deciphera Pharma of the US and its fast-growing gastrointestinal stromal tumour (
Mere months after announcing a partnership to develop digital support tools for cancer patients, Huma Therapeutics and Merck KGaA have launched their first app in the UK.
Johnson & Johnson’s Rybrevant is on the brink of EU approval as a treatment for a subset of patients with newly diagnosed EGFR-positive lung cancer, after a recommenda
Endeavor BioMedicines has completed a third round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
Roche chief executive Thomas Schinecker said today that one in five of the pharma division’s pipel
Editor's Picks
Newsletters and Deep Dive
digital magazine